The association between serum uric acid to high density lipoprotein ratio and cardiometabolic-related risk in adults with obesity.

IF 3.7 3区医学 Q2 Medicine

Endocrine Pub Date : 2025-05-21 DOI:10.1007/s12020-025-04258-z

Luisella Vigna, Patrizia Landi, Melania Gaggini, Filomena Napolitano, Francesca Gori, Alessandra Piontini, Fabrizio Minichilli, Cristina Vassalle

{"title":"The association between serum uric acid to high density lipoprotein ratio and cardiometabolic-related risk in adults with obesity.","authors":"Luisella Vigna, Patrizia Landi, Melania Gaggini, Filomena Napolitano, Francesca Gori, Alessandra Piontini, Fabrizio Minichilli, Cristina Vassalle","doi":"10.1007/s12020-025-04258-z","DOIUrl":null,"url":null,"abstract":"Introduction: The uric acid (UA) to high density lipoproteins (HDL) ratio (UHR) has recently emerged as a new effective biomarker for inflammation and cardiometabolic diseases. However, the relationship between UHR and the metabolic syndrome and its components and other cardiometabolic parameters in individuals with obesity remains to be further investigated.Aim: To evaluate UHR levels in participants with obesity, as well correlation of UHR with other cardiometabolic risk factors. Moreover, the predictive value of UHR for insulin resistance, metabolic syndrome and visceral adiposity (estimated by using waist circumference) was evaluated, also with respect to UHR components (UA and HDL alone).Methods: Participants were enrolled from the Center of Obesity and Work, Occupational Health Unit of Clinica del Lavoro \"L. Devoto\", Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan (Italy) and divided into two groups according to body mass index (BMI) values; controls (when BMI < 30 kg/m2) and participants with obesity (when BMI ≥ 30 kg/m2).Results: A total of 1743 (1268 females, mean age 52 ± 14 years) was enrolled in the study. Multiple logistic regression analysis indicated a significant association between obesity and UHR (odds ratio (95% confidence intervals) p value; 1.1 (1-1.1) < 0.01) after adjustment for different biomarkers of cardiometabolic risk. The area under the ROC curve (AUC) of UHR was significantly larger compared with the use of HDL or UA alone for insulin resistance (0.73, 0.3 and 0.67, respectively), metabolic syndrome (0.77, 0.26 and 0.69, respectively) and waist circumference (0.65, 0.37 and 0.62, respectively).Conclusion: Elevated UHR, better than UA or HDL alone, demonstrates a significant correlation with obesity and cardiometabolic parameters, so it could be used as a potential indicator of cardiometabolic risk in this clinical setting.","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04258-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The uric acid (UA) to high density lipoproteins (HDL) ratio (UHR) has recently emerged as a new effective biomarker for inflammation and cardiometabolic diseases. However, the relationship between UHR and the metabolic syndrome and its components and other cardiometabolic parameters in individuals with obesity remains to be further investigated.

Aim: To evaluate UHR levels in participants with obesity, as well correlation of UHR with other cardiometabolic risk factors. Moreover, the predictive value of UHR for insulin resistance, metabolic syndrome and visceral adiposity (estimated by using waist circumference) was evaluated, also with respect to UHR components (UA and HDL alone).

Methods: Participants were enrolled from the Center of Obesity and Work, Occupational Health Unit of Clinica del Lavoro "L. Devoto", Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan (Italy) and divided into two groups according to body mass index (BMI) values; controls (when BMI < 30 kg/m²) and participants with obesity (when BMI ≥ 30 kg/m²).

Results: A total of 1743 (1268 females, mean age 52 ± 14 years) was enrolled in the study. Multiple logistic regression analysis indicated a significant association between obesity and UHR (odds ratio (95% confidence intervals) p value; 1.1 (1-1.1) < 0.01) after adjustment for different biomarkers of cardiometabolic risk. The area under the ROC curve (AUC) of UHR was significantly larger compared with the use of HDL or UA alone for insulin resistance (0.73, 0.3 and 0.67, respectively), metabolic syndrome (0.77, 0.26 and 0.69, respectively) and waist circumference (0.65, 0.37 and 0.62, respectively).

Conclusion: Elevated UHR, better than UA or HDL alone, demonstrates a significant correlation with obesity and cardiometabolic parameters, so it could be used as a potential indicator of cardiometabolic risk in this clinical setting.

查看原文本刊更多论文

成人肥胖患者血清尿酸与高密度脂蛋白比值与心脏代谢相关风险的关系

尿酸（UA）与高密度脂蛋白（HDL）比值（UHR）近年来成为炎症和心脏代谢疾病的一种新的有效生物标志物。然而，UHR与肥胖个体代谢综合征及其成分和其他心脏代谢参数之间的关系仍有待进一步研究。目的：评估肥胖参与者的UHR水平，以及UHR与其他心脏代谢危险因素的相关性。此外，还评估了UHR对胰岛素抵抗、代谢综合征和内脏肥胖（通过腰围估计）的预测价值，以及UHR成分（单独的UA和HDL）的预测价值。方法：研究对象来自意大利米兰Ospedale Maggiore Policlinico、funddazione IRCCS Ca' Granda职业卫生诊所“L. Devoto”职业卫生中心肥胖与工作中心，根据体重指数（BMI）分为两组；对照组（BMI为2时）和肥胖参与者（BMI≥30 kg/m2时）。结果：共纳入1743例（女性1268例，平均年龄52±14岁）。多元logistic回归分析显示肥胖与UHR之间存在显著相关性(优势比（95%置信区间）p值；1.1（1-1.1）结论：UHR升高与肥胖和心脏代谢参数的相关性优于单独的UA或HDL，因此UHR可作为该临床环境中心脏代谢风险的潜在指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine 医学-内分泌学与代谢

CiteScore

6.40

自引率

5.40%

发文量

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.